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(±)-(DX)-[1,2-Bis(4-fluorophenyi)ethylenediamine]dichloroplatinum(H 
Antineoplastic 
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Synthesis 
The racemic dichloroplatinum(ll) complex D-17446 and 
its meso configurated diastereoisomer were synthesized 
according to Scheme 1 by reacting K 2PtCI 4 with (D,L)- and 
n7eso1,2-bis(4-fluorophenyl)ethyienediamine in water at 
pH 5.5-6.5 at temperatures below 60°. Complexation with 
K2PtI4 led to the diiodoplatinum(ll) complexes. The corre-
sponding sulfatoplatinum(ll) complexes were obtained by 
addition of A g 2 S 0 4 to the aqueous suspensions of the diio-
doplatinum(ll) complexes. 
The diastereoisomeric 1,2-bis(4-fluorophenyi)ethylene-
diamines were synthesized according to the method de-
scribed by Vögtle and Goldschmitt (1). Meso-1 ,2-bis(4-fluo-
rophenyl)ethyienediamine was obtained from 4-fluoro-
benzaldehyde and meso-(2-hydroxyphenyl)ethyienedia-
mine by a stereospecific meso-meso diaza-Cope-rear-
rangement reaction and subsequent hydrolysis of the prod-
uct with H 2 S 0 4 . The racemic Compound was synthesized by 
mesoox stereoisomerization of N,W-bis(4-fluorobenzyli-
dene)-meso-1,2-bis(4-fluorophenyl) ethylenediamine at 
temperatures below 200° followed by hydrolysis with 
H^Od. Separation of the diastereoisomers was carried out 
by fractional crystallization of the dihydrosulfates yielding 
the less water soluble o.L-diamine. 
Introduction 
The search for new antitumor cisplatinum anaiogs is stim-
ulated by the desire to find a drug for p.o. administration with 
either less severe side effects or with activity against tumors 
that exhibit primary or acquired resistance to cisplatin. So 
far in the clinic no platinum-containing drug has clearly dem-
onstrated therapeutic effect in the treatment of breast Can-
cer. 
Investigations on the influence of ring substituents on the 
antitumor effect of dich!oro(1,2-diphenyiethylenedia-
mine)platinum(ll) complexes uncovered D-17446 (the ra-
cemic 4-fiuoro-substituted derivative) as the most active 
Compound against the P388 leukemia prescreen in vivo and 
the MDA-MB-231 human breast Cancer cell line in vitro (2). 
Pharmacological Actions 
Resolution of D-17446 into its enantiomers failed to en-
hance the antineoplastic effect (3). The antitumor activity of 
D-17446 could neither be improved by the synthesis of iso-
mers containing fiuoride in the Ortho and meta position (4, 
5) nor by the introduction of a second fluorine substituent 
into the 1,2-diphenylethylenediamine ligand (6, 7). 
The antileukemic activity of D-17446 and its meso-confi-
gurated diastereoisomer on the P388 D1 cell line after 48 h 
of in vitro drug exposure were comparable with cisplatin. 
However, D-17446 produced the half maximal effect much 
faster (t1/2 = 3.3 h) than its mesoconfigurated counterpart. 
Inhibition of pH]-thymidine incorporation after short-term 
contact of the cells with D-17446 was similar to the inhibition 
observed after permanent drug exposure, thus indicating a 
rapid uptake of this platinum complex by the tumor cell (5). 
In addition D-17446 was markediy active on a subiine of the 
L1210 leukemia of the mouse which is about 100-fold resis-
tant to cisplatin (5). 
The determination of acute toxicity after i.p. injection of 
D-17446 resulted in an LD50 of > 1000 mg/kg mouse (Asta 
communication). However, this result is compromised by 
the extremely low water solubiiity of the dichloro complex. 
Remarkably, (o.L)-[1t2-bis(4-fluoropheny!)ethylenedi-
amine]dich!orop!atinum(l!) (D-17446) inhibited both the hör-
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Scheme 1: Synthesis of D-17446 
mone-insensitive MDA-MB-231 (2) and the hormone-sensi-
tive MCF-7 (3) human breast Cancer cell line in vitro. This 
mammary tumor inhibiting activity was not restricted to in w-
froexperiments. The more soluble sulfatoplatinum(ll) deriv-
ative of D-17446 (D-17446-S04) was also highly effective in 
vivo on the ovarian-dependent and the hormone-insensitive 
MXT mammary Carcinoma of the B6D2F1 mouse (8). 
For the following detailed investigations we chose a rep-
resentative panel of human mammary Carcinoma cell lines 
(MDA-MB-231, MCF-7, ZR-75-1 and T-47-D) characterized 
by approximately ten-fold in vitro resistance to cisplatin 
compared with the murine MXT mammary Carcinoma cells. 
AH breast cancer models were available in cell culture and 
as solid tumors implanted subcutaneousiy into the flank of 
NMRI nude mice. For in vitro chemosensitivity testing we 
developed a computerized kinetic crystal violet microassay 
(10,11) based on the quantitation of the total dye binding ca-
pacity of the cells which is directly proportional to the tumor 
mass. This method allows the convenient coilection of large 
sets of data necessary for the analysis of the proiiferation ki-
netics of the drug-treated cell population and the untreated 
control, providing results of high Statistical significance. By 
Variation of the experimental protocol important data such 
as drug stability, effective concentration, the time required 
for net cell kill (a prerequisite for a curative effect) for the es-
tablishment of optimal in vivo schedules can be easily ob-
tained in vitro. 
The diastereoisomeric [1,2-bis(4-fluorophenyl)ethylene-
diamine]dichloroplatinum(ll) complexes and cisplatin were 
extensively tested on the MDA-MB-231, MCF-7, ZR-75-1 
and T-47-D human breast Cancer cell lines in vitro. In all ex-
periments with permanent drug exposure D-17446 was su-
perior to the lead Compound cisplatin. Except for minor 
quantitative differences in chemosensitivity to plati-
num-containing drugs (cell lines are ranked according to in-
creasing sensitivity: MDA-MB-231 < MCF-7 less than or 
equal to ZR-75-1 < T-47-D), the results were qualitatively 
the same. The Situation is illustrated for MCF-7 in Figure 1. 
MCF-7 cells were treated with D-17446-S04 (racemate), 
the mesoconfigurated analog and cisplatin in three concen-
trations (0.5,1 and 5 mcM) (the Start of the time axis in Fig. 
1). In this experiment the drug (and vehicle) containing cul-
ture media were not changed during the entire incubation 
period. 
The extent of dose dependence decreased from the 
meso-configurated Compound (Fig. 1B) to the racemate 
(Fig. 1A) to cisplatin (Fig. 1C), parallelied by an increase in 
the antiproliferative activity for the 0.5 and 1 mcM doses. At 
the highest concentration (5 mcM) all three platinum com-
plexes produced complete Inhibition of cell proiiferation. 
Comparative studies with the dichloroplatinum(ll) Com-
pound D-17446 provided results which were similar to the 
data obtained from analogous experiments with 
(o,L)-[1,2-bis(4-fluorophenyl)ethylenediamine]sulfatoplati-
num(ll). 
Unfortunately, these platinum complexes and cisplatin 
were ineffective on MDA-MB-231, MCF-7 and ZR-75-1 im-
planted into nude mice (Fig. 2), when the drugs were 
applied according to conventional schedules (three times a 
week, s.c. and Lp.). 
To find the optimal conditions for an in wVoschedule and 
the time of drug exposure necessary to achieve maximal in-
hibitory effects, MCF-7 cells were incubated in the presence 
of 5 mcM of D-17446-S04 for 4, 6 and 12 h. After the indi-
cated times of drug exposure the platinum complexes were 
removed by medium exchange and their antineoplastic ac-
0 10 20 30 40 50 60 
Time [d] 
Fig. 2. 
tivity was determined after various times of incubation of the 
cuitures in f resh medium. Direct proportionality of the dura-
tion of drug exposure and the inhibition of cell proiiferation 
was observed. All three platinum complexes displayed 
maximum activity after 12 h. Surprisingly, after 6 h of incuba-
tion, D-17446-S04 and cisplatin produced comparable de-
grees of inhibition (around 80%), although the 
(o,L)-[1,2-bis(4-fluorophenyi)ethylenediamine]sulfatoplati-
num(ll) was definitely less stable than cisplatin in culture 
medium (12). On the contrary, 12 h of drug exposure were 
necessary for its meso-conf igurated counterpart to become 
equiactive at the given concentration. In addition, the onset 
of action of D-17446-S04 was markedly faster in compari-
son with cisplatin and its meso-configurated counterpart. 
Becaue of the relatively fast inactivation of D-17446-S04 
(12), the lesions which finally cause inhibition of cell proiifer-
ation and cell death must be produced within the first few 
hours of the chemosensitivity assay. 
MCF-7 cells were incubated with 5 mcM (O,L)-[1 ,2-bis-(4-
fluorophenyl)ethylenediamine]sulfatoplatinum(ll), meso 
[1,2 - bis(4 - fluorophenyl) ethylenediamine] sulfatopiati-
num(ll) and cisplatin. Platinum uptake was determined by 
neutron activation analysis (NAA). In contrastto cisplatin, in 
the case of the diastereoisomeric [1,2-bis(4-fluorophe-
nyl)ethylenediamine]sulfatoplatinum(ll) complexes plati-
num was selectively accumulated with high specificity 
(Fig. 3). ForD-17446-S04accumu!ation was very rapid, i.e., 
an intracellular Pt concentration of around 70 mcM was 
reached within 4 h (12). 
Platinum uptake for Compound D-17446-S04 was highly 
specific and faster than for its /nesoconfigurated counter-
part. This discrimination between diastereoisomers Sup-
ports evidence that the uptake of the diastereoisomeric 
[1,2 - bis - (4 - fluorophenyl)ethylenediamine]suIfatoplati-
num(ll) complexes by MCF-7 cells is carrier mediated. 
Pharmacokinetics 
Measurements of platinum by NAA in plasma and in its ul-
trafiltrate after application of 10 mcmol/kg of D-17446-S04 
to NMRI nude mice clearly demonstrated that neither the 
low water solubility nor the resorption of this platinum com-
plex caused the negative results in vivo. Within the first few 
hours, plasma concentrations of around 10 mcM were 
reached after a Single i.p. injection. However, the 
(1,2-bis(4-fluorophenyl)ethylenediamine]platinum(ll) com-
plexes were extensively bound to plasma protein (Fig. 4). As 
a consequence, in the nude mouse the effective drug con-
centration is far too low to produce a therapeutic effect. 
In model experiments using human serum albumin (HSA) 
at concentrations equivalent to the in vitro (3.4 mg/ml) and 
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the in vivo (34 mg/ml) Situation, we studied the protein bind« 
ing capacity of selected platinum complexes. Albumin dis-
solved in PBS was incubated in the presence of 3 mcM plati-
num complex at 37°. After 4 h, total and free (size of 
exclusion: 10 Kd) platinum was measured by AAS. The re-
sults are summarized in Table I. Compared with carbopiatin 
and cisplatin the [1,2-bis(4-fluorophenyl)ethylenedi-
amine]platinum(ll) complexes bound strongly to serum al-
bumin. 
Table I: Binding of platinum complexes to 3.4 and 34 mg/ml HSA 
dissotved in PBS. After 4 h of incubation with 3 mcM platinum 
complex at 37° ultrafiltrable platinum was determined by AAS. 
Free Platinum in f 
HSA Concentration [mg/ml] 
Compound 3.4 34 
racemic-4F-PtS04 
(D-17446«S0 4) 
38 3.4 
meso-4F-PtS0 4 42 2.7 
racemic-4F-PtCI2 (D-17446) 51 8.7 
Cisplatin 92 43 
Carbopiatin >90 >90 
The reactivities of the intenmediately formed diaquaplati-
num(ll) species (active drug) were identical, regardless of 
the differences in stereochemistry. Under conditions simu-
lating both the in vitro (3.4 mg/ml) and the in vivo Situation 
(34 mg/ml) D-17446 was slightly less reactive than 
D-17446-S04. 
Surprisingly, protein binding depended considerably on 
the serum albumin concentration, although in both exper-
imental series a high molar excess of HSA was used (Table 
I). Equilibrium dialysis experiments revealed that platinum 
was bound irreversibly. On this basis the discrepancy be-
tween the positive results of the in vitro chemosensitivity as-
says and therapeutic ineffectiveness in vivo can easily be 
explained. 
Conciusions 
In summary, D-17446 is a promising candidate for further 
development because of some principal advantages com-
pared with the universe of new cisplatinum analogs investi-
gated in early phases of preclinical trials: 1) activity on tumor 
models (e.g., 11210) which are resistantto cisplatin; 2) high 
activity against both hormone-sensitive and hormone-in-
sensitive mammary carcinomas; 3) specific accumulation 
by human hormone-sensitive and hormone-insensitive 
mammary carcinomas due to the 1,2-bis(4-fluorophe-
nyl)ethylenediamine ligand. The poor bioavailabiiity caused 
by the high reactivity of the presently available sulfato and 
dichloro(1,2 - bis(4 - fluorophenyi) ethylenediamine] piati-
num(ll) complexes seems to be the major limitation of this 
class of cisplatinum analogs. 
Manufacturer 
Asta Pharma (Germany). 
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Legends to the Figures 
Fig. 1: Long term incubation of MCF-7 cells with the platinum complexes. Effect of drug 
concentration (•) 0.5 /xM; (o) 1 /xM; (A) 5 fiM on cell proiiferation (•) control. 
Panel A: D,L-[1,2-bis(4-fluorophenyl)ethylenediamine]sulfatoplatinum(II) 
Panel B: [meso-1,2-bis(4-fluorophenyl)ethylenediamine]sulfatoplatinum(II) 
Panel C: cisplatin. 
Fig. 2: Effect of D-17446 and its meso-configurated counterpart on the proiiferation of the 
human MCF-7 mammary Carcinoma implanted into NMRI nude mice (12 animals per 
group). The platinum complexes were administered at a dose of 10 ptmol/kg L p. three times 
a week. The arrow indicates the beginning of treatment. 
Inset: Mean changes of body weight. At the maximum tolerated dose (3 /imol/kg i. p.) cis-
platin was also ineffective (data not shown). 
(•) control 
( • ) D,L-[l,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) (D-17446) 
(A) [meso-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). 
Fig. 3: Platinum accumulation by MCF-7 cells. The cultures were treated with 5JJM platinum 
complex in M E M Eagle's medium containing 10% FCS. 
The accumulated platinum was measured by neutron activation analysis and is expressed on 
the basis of mean fiM intracellular concentration. 
(A) D,L-[1,2-bis(4-fluorophenyl)ethylenediamine]sulfatoplatinum(II) 
(A) [meso-l,2-bis(4-fluorophenyl)ethylenediamine]sulfatoplatinum(II) 
(o) cisplatin 
Fig. 4: Pharmacokinetics of D-17446-SO^ after a Single i. p. injection (10 /xmol/kg, vehicle 
water) into female NMRI nude mice. 
Platinum in plasma (•) and its ultrafiltrate (•) was measured by N A A . 
